Afatinib was approved by the U.S. FDA in 2018 for metastatic NSCLC with uncommon non-drug-resistant EGFR mutations (L861Q, G719X, and/or S768I) (5). This evidence concerns the gene EGFR and non-small cell lung carcinoma.